Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients
Authors:
- Maeve MulloolyMMMaeve Mullooly
- Sarah J. NyanteSNSarah J. Nyante
- Ruth M. PfeifferRPRuth M. Pfeiffer
- Renata CoraRCRenata Cora
- Donna ButcherDBDonna Butcher
- Lawrence SternbergLSLawrence Sternberg
- Erin J. Aiello BowlesEBErin J. Aiello Bowles
- Shaoqi FanSFShaoqi Fan
- Jonine D. FigueroaJFJonine D. Figueroa
- Sheila WeinmannSWSheila Weinmann
- Robert N. HooverRHRobert N. Hoover
- Louise A. BrintonLBLouise A. Brinton
Open Access
- 4 November 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (11) , 1868
Abstract
Mammographic breast density (MD) reflects breast fibroglandular content. Its decline following adjuvant tamoxifen treated, estrogen receptor (ER)-positive breast cancer has been associated with improved outcomes. Breast cancers arise from structures termed lobules, and lower MD is associated with increased age-related lobule involution. We assessed whether pre-treatment involution influenced associations between MD decline and risk of breast cancer-specific death. ER-positive tamoxifen treated patients diagnosed at Kaiser Permanente Northwest (1990–2008) were defined as cases who died of breast cancer (n = 54) and matched controls (remained alive over similar follow-up; n = 180). Lobule involution was assessed by examining terminal duct lobular units (TDLUs) in benign tissues surrounding cancers as TDLU count/mm2, median span and acini count/TDLU. MD (%) was measured in the unaffected breast at baseline (median 6-months before) and follow-up (median 12-months after tamoxifen initiation). TDLU measures and baseline MD were positively associated among controls (p < 0.05). In multivariable regression models, MD decline (≥10%) was associated with reduced risk of breast cancer-specific death before (odds ratio (OR): 0.41, 95% CI: 0.18–0.92) and after (OR: 0.41, 95% CI: 0.18–0.94) adjustment for TDLU count/mm2, TDLU span (OR: 0.34, 95% CI: 0.14–0.84), and acini count/TDLU (OR: 0.33, 95% CI: 0.13–0.81). MD decline following adjuvant tamoxifen is associated with reduced risk of breast cancer-specific death, irrespective of pre-treatment lobule involution.Keywords
Funding Information
- Intramural Research Program of the National Cancer Institute at the National Institutes of Health (NCI-funded contracts HHSN261200-900017C and HHSN261201-200304P)
- Health Research Board in Ireland (CPFPR-2013-1)
This publication has 32 references indexed in Scilit:
- Analysis of terminal duct lobular unit involution in luminal A and basal breast cancersBreast Cancer Research, 2012
- Quantitative Assessment of Mammary Gland Density in Rodents Using Digital Image AnalysisBiological Procedures Online, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Association Between Mammographic Density and Age-Related Lobular Involution of the BreastJournal of Clinical Oncology, 2010
- Novel Breast Tissue Feature Strongly Associated With Risk of Breast CancerJournal of Clinical Oncology, 2009
- Lobule type and subsequent breast cancer risk: Results from the Nurses' Health StudiesCancer, 2009
- Mammographic density, lobular involution, and risk of breast cancerBritish Journal of Cancer, 2008
- Age-Related Lobular Involution and Risk of Breast CancerJNCI: Journal of the National Cancer Institute, 2006
- Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2006
- The quantitative analysis of mammographic densitiesPhysics in Medicine & Biology, 1994